Markets:

Overview

News

Currencies

International

Treasuries

Sangamo Therapeutics, Inc. - Common Stock (NQ:SGMO)

0.3799 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Feb 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Sangamo Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Zeta Global, Spirit Airlines And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

November 12, 2024

Via Benzinga

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

Sangamo Therapeutics's Earnings Outlook ↗

November 11, 2024

Via Benzinga

Booz Allen Posts Upbeat Q3 Earnings, Joins Deckers Outdoor, Saia, Boyd Gaming And Other Big Stocks Moving Higher On Friday ↗

October 25, 2024

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 23, 2024

Via Benzinga

4 Analysts Have This To Say About Sangamo Therapeutics ↗

October 23, 2024

Via Benzinga

Why Is Sangamo Therapeutics (SGMO) Stock Up 52% Today? ↗

August 06, 2024

Sangamo Therapeutics stock is heading higher on Tuesday as SGMO investors react to a new $50 million license agreement.

Via InvestorPlace

Peering Into Sangamo Therapeutics's Recent Short Interest ↗

July 25, 2024

Via Benzinga

Nasdaq Turns Higher; Verizon Shares Fall After Q3 Results ↗

October 22, 2024

Via Benzinga

What's Going On With Sangamo Therapeutics Shares Tuesday? ↗

October 22, 2024

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares are moving higher Tuesday after the company announced the FDA approved an accelerated pathway for ST-920, a potential gene therapy for the treatment of...

Via Benzinga

Crude Oil Rises Sharply; 3M Posts Upbeat Earnings ↗

October 22, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 22, 2024

Via Benzinga

Dow Falls Over 150 Points; General Motors Tops Q3 Views ↗

October 22, 2024

Via Benzinga

Topics Stocks

4 Analysts Assess Sangamo Therapeutics: What You Need To Know ↗

March 13, 2024

Via Benzinga

FDA Approves Pfizer's Second Hemophilia Drug With Six Months ↗

October 14, 2024

Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly treatment reduces bleeding rates and offers convenience via an...

Via Benzinga

Why Sangamo Therapeutics Stock Is Soaring ↗

August 06, 2024

Sangamo Therapeutics shares are trading higher Tuesday after the company announced it has entered into a license agreement with Genentech to develop intravenously administered genomic medicines for...

Via Benzinga

Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

July 26, 2024

Via Benzinga

Why Is Sangamo Therapeutics (SGMO) Stock Up 40% Today? ↗

July 24, 2024

Little-known firm Sangamo Therapeutics is surging today, with SGMO stock up more than 40% on promising late-stage trial results.

Via InvestorPlace

Crude Oil Gains 1%; AT&T Shares Rise After Q2 Earnings ↗

July 24, 2024

Via Benzinga

Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

July 24, 2024

Via Benzinga

Dow Tumbles 300 Points; Tesla Shares Plunge After Q2 Results ↗

July 24, 2024

Via Benzinga

Topics Stocks

Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study ↗

July 24, 2024

Pfizer's Phase 3 AFFINE study of giroctocogene fitelparvovec gene therapy for hemophilia A meets key endpoints, showing a significant reduction in annualized bleeding rate.

Via Benzinga

Critical Insights From Sangamo Therapeutics Analyst Ratings: What You Need To Know ↗

May 15, 2024

Via Benzinga

SGMO Stock Earnings: Sangamo Therapeutics Misses EPS, Misses Revenue for Q1 2024 ↗

May 09, 2024

SGMO stock results show that Sangamo Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Friday's Intraday Session ↗

March 22, 2024

Via Benzinga

Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform ↗

March 19, 2024

Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, promising CNS-targeted gene therapies and strategic partnerships driving long-term...

Via Benzinga

Earnings Scheduled For March 13, 2024 ↗

March 13, 2024

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

February 19, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

February 12, 2024

Via Benzinga

Why Palantir Technologies Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket ↗

February 06, 2024

Shares of Palantir Technologies Inc. (NYSE: PLTR) rose sharply during today’s pre-market trading after the company reported better-than-expected fourth-quarter sales results and issued guidance.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sangamo Therapeutics, Inc. - Common Stock (NQ:SGMO)

Headline News about Sangamo Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today